Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer Fast Track designation opens the potential for expedited development and review with the US FDAFast Track was granted based on the promising data package from Immutep, including from Immutep’s Phase...

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...

Immutep Operational Update Efti clinical trial status updatesExcellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 Sydney, AUSTRALIA, Dec. ...